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Abstract: INTRODUCTION: The latest guidelines of the American Society of Clinical Oncology/College
of American Pathologists (ASCO/CAP) to test Human Epidermal Growth Factor Receptor 2 (HER2)
in breast cancer after being revised in 2008 underwent a second modification in October 2013. The
modification includes changes in cut-offs: 10% strong membranous staining for score 3+ on immunohis-
tochemistry (IHC) (previously 30%) and using the ratio of >2 or absolute gene-copy-number (6 or more)
alone or in combination with each other by in-situ-hybridisation technology (previously >2.2 and average
copy-number of 6 or more). Hereby we addressed the question, which impact the modified cut-offs had
on overall HER2-positivity in a single institution. METHODS: We prospectively analysed 617 consecu-
tive diagnostic breast-cancer cases which underwent double HER2 testing by immunohistochemistry and
fluorescent in-situ hybridisation (FISH), using the modified 2013 ASCO/CAP-guidelines for one year
(October 2013-October 2014). Results were compared with HER2-test results on 1,528 consecutive diag-
nostic breast-cancer cases from two previous years (2011-2012), using the 2008 ASCO/CAP guidelines,
also tested with IHC and FISH in each case. RESULTS: Between October 2013 and October 2014, overall
HER2-positivity was 15.8% (98 of 617 cases were either IHC 3+ or FISH amplified). 79 of 617 cases (13%)
were IHC 3+, 96 of 617 cases (15.5%) were FISH amplified. Equivocal cases were seen in 25 of 617 cases
(4.1%). 22 of 25 equivocal cases (88%) in 2013-2014 were IHC 1+ or 2+. In 13 equivocal cases, there was
a repeated IHC/FISH testing: 2 of 13 cases (15%) became FISH amplified, 1 of 13 cases (7.5%) became
IHC 3+. In 2011-2012, overall HER2-positivity (IHC/FISH) was 13.8% (211 of 1,528 cases). 185 of 1,528
cases (12%) were 3+ on IHC, 181 of 1,522 cases (12%) were amplified by FISH. Six of 1,528 cases were
equivocal by FISH, and interpreted as non-amplified (0.3%). CONCLUSIONS: Applying the modified
ASCO/CAP guidelines from 2013 resulted in an increase (2%) in overall HER2-positivity rate compared
to overall-HER2-positivity rate using the 2008 ASCO/CAP guidelines. The increased positivity rate
was mainly due to more FISH-positive cases (3.5% more than until 2013). The high rate of equivocal
cases (4.1%) did not contribute to increase in overall HER2-positivity, but resulted in delay in definitive
HER2-status.
DOI: 10.1371/journal.pone.0140652
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The latest guidelines of the American Society of Clinical Oncology/College of American Pathol-
ogists (ASCO/CAP) to test Human Epidermal Growth Factor Receptor 2 (HER2) in breast
cancer after being revised in 2008 underwent a secondmodification in October 2013. Themod-
ification includes changes in cut-offs: 10% strongmembranous staining for score 3+ on immu-
nohistochemistry (IHC) (previously 30%) and using the ratio of >2 or absolute gene-copy-
number (6 or more) alone or in combination with each other by in-situ-hybridisation technology
(previously >2.2 and average copy-number of 6 or more). Hereby we addressed the question,
which impact the modified cut-offs had on overall HER2-positivity in a single institution.
Methods
We prospectively analysed 617 consecutive diagnostic breast-cancer cases which under-
went double HER2 testing by immunohistochemistry and fluorescent in-situ hybridisation
(FISH), using the modified 2013 ASCO/CAP-guidelines for one year (October 2013–Octo-
ber 2014). Results were compared with HER2-test results on 1,528 consecutive diagnostic
breast-cancer cases from two previous years (2011–2012), using the 2008 ASCO/CAP
guidelines, also tested with IHC and FISH in each case.
Results
Between October 2013 and October 2014, overall HER2-positivity was 15.8% (98 of 617
cases were either IHC 3+ or FISH amplified). 79 of 617 cases (13%) were IHC 3+, 96 of 617
cases (15.5%) were FISH amplified. Equivocal cases were seen in 25 of 617 cases (4.1%).
22 of 25 equivocal cases (88%) in 2013–2014 were IHC 1+ or 2+. In 13 equivocal cases,
there was a repeated IHC/FISH testing: 2 of 13 cases (15%) became FISH amplified, 1 of
13 cases (7.5%) became IHC 3+. In 2011–2012, overall HER2-positivity (IHC/FISH) was
13.8% (211 of 1,528 cases). 185 of 1,528 cases (12%) were 3+ on IHC, 181 of 1,522 cases
(12%) were amplified by FISH. Six of 1,528 cases were equivocal by FISH, and interpreted
as non-amplified (0.3%).
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Conclusions
Applying the modified ASCO/CAP guidelines from 2013 resulted in an increase (2%) in
overall HER2-positivity rate compared to overall-HER2-positivity rate using the 2008
ASCO/CAP guidelines. The increased positivity rate was mainly due to more FISH-positive
cases (3.5%more than until 2013). The high rate of equivocal cases (4.1%) did not contrib-
ute to increase in overall HER2-positivity, but resulted in delay in definitive HER2-status.
Introduction
The assessment of HER2 status in breast cancer is a part of routine tests on primary and / or on
recurring lesions [1–3]. HER2 assays are increasingly carried out on preoperative core needle
or vacuum assisted breast biopsies due to preoperative therapy planning particularly in terms
of neoadjuvant chemotherapy options. Thus surgical breast specimens serve as additional
options for HER2 assays as well. International guidelines for scoring of immunohistohemical
and in situ hybridisation signals are available and widely used in HER2 testing in breast cancer
[1, 3–5] Practising pathologists, being involved in breast pathology diagnostic service, need
special training and long term expertise in order to achieve reproducible and standardized
HER2 test results using the international guidelines [2, 6, 7]. Exact rate of HER2 positive breast
cancer within a given institution or in a predefined timeframe or geographic area, are estimated
upon the positivity rate, reported in the pathology reports. Modifying scoring criteria can con-
sequently result in increase or decrease of reported HER2 positivity [6]. The first adjustment of
the original Federal Drug Administration (FDA) guidelines and their replacement by the
ASCO/CAP guidelines in 2008 resulted in a decrease of overall HER2 positivity rate from 17–
20% to 13–14% [3, 6]. However, additionally to cut-off modification in the guidelines, the
introduction of mammography screening and the detection of smaller tumors may have also
contributed to the decrease in HER2 positivity rate [6]. The ASCO/CAP HER2 testing guide-
lines underwent a revision some years ago, and the newly published recommendation in Octo-
ber 2013 resulted in modification of HER2 scoring criteria again [4]. Basically, the cut-offs
were downgraded and the definition of polysomic cases and the significance of the HER2/
CEP17 ratio were newly defined.
In this study we compared overall HER2 positivity rate prior to the introduction of the mod-
ified ASCO/CAP guidelines from October 2013 with the ones using the new definitions from
this time.
We prospectively analysed consecutive HER2 diagnostic cases from the period of 2011–
2012 (n = 1528) and compared with HER2 test results between October 2013 and October
2014 (n = 617). All breast cancer cases underwent double HER2 testing by immunohistochem-
istry and fluorescence in situ hybridisation according to the institutional guidelines as pub-
lished earlier [6]. We addressed the question how the modification of the guidelines and the
cut-offs influenced the HER2 positivity rate and what impact resulted after this modification
on diagnostic HER2 testing in breast cancer.
Material and Methods
Patient’s cohort
Consecutive patients with the diagnosis of invasive breast carcinoma undergoing HER2 testing
at the Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland were
analysed. Two periods were evaluated, 2011–2012 (two years) and from October 2013 to
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October 2014 (one year). Data on HER2 status from 2011–2012 were partially included in a
previous paper, cases with polysomy or equivocal HER2 status were not included in this previ-
ous study [6]. In the period of 2011–2012, there were 1528 patients analysed, in the period of
October 2013-October 2014, there were 617 patients, who underwent HER2 testing. The study
was a prospective data analysis of an existing data bank without any additional experiment on
human tissue. This study is a part of a previously approved project by the Ethical Committee of
Canton Zurich (KEK-2012-553) and was conducted in a completely anonymized way.
Informed consent was not required for the study due to the anonymity of the data used.
Laboratory data
During the whole period (2011–2014), the same laboratory procedure for IHC and FISH was
applied as published earlier [6].
Diagnostic criteria 2011–2012
Protein expression and gene copy number score were scored using the time current ASCO/
CAP guidelines as published earlier [3, 6].
HER2 immunohistochemistry. Score 0: no staining.
Score 1+: weak and incomplete membrane staining in less than 10% of the invasive tumor
cells.
Score 2+: weak complete staining of the membrane in more than 10% of invasive cancer
cells.
Score 3+: strong complete homogenous membrane staining in more than 30% of the inva-
sive tumor cells.
HER2 FISH. HER2 signals were scored as follows: the number of signal copies and the
ratios (HER2/CEP17) were calculated: gene copies (> 6) or cluster formations (small clusters ~
6 copies, larger clusters ~ 12 copies) were counted. A ratio> 2.2 was set as amplified status; a
ratio< 1.8 was negative, and a ratio of 1.8–2.2 was referred to as equivocal (according the 2008
guidelines) and using ratio> 2.2 and> 6 HER2 gene copies (in> 10% of the tumor cells) for a
positive status (according to 2008 guidelines). If ratio was<2.2, the gene copy number was not
considered alone as amplified based on the definitions in the recommendations in Tables 2 and
4 in the ASCO/CAP 2008 guidelines for dual FISH probes [3]
Diagnostic criteria 2013–2014
Protein expression and gene copy number score were scored using the latest ASCO/CAP
guidelines published in October 2013 [4].
HER2 immunohistochemistry. Score 0: no stain or faint incomplete membrane stain in
not more than 10% within the cells. Score 1+: weak and incomplete membrane staining in
more than 10% of the tumor surface. Score 2+: Complete intense membrane staining in not
more than 10% of the invasive tumor cells or weak/moderate heterogeneous incomplete stain-
ing in more than 10% of the invasive tumor cells.
Score 3+: strong complete homogenous membrane staining in more than 10% of the inva-
sive tumor cells.
HER2 FISH. HER2 gene copy signals were scored as follows:
Positive status was defined either as an average HER2 gene copy numbers of 6 at cases with
a HER2/CEP17 ratio of less than 2 or a HER2/CEP17 ratio of 2 or more independently of the
average gene copy number.
Negative status was defined as average gene copy number of less than 4 with a HER2/CEP17
ratio of less than 2.
HER2 Status, ASCO/CAP Guidelines
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Equivocal cases were defined as average gene copy number of at least 4 and less than 6 with
a HER2/CEP17 ratio of less than 2.
Results
Comparison of the overall HER2 positivity rate in two periods with at the time current guide-
lines (ASCO/CAP 2008 and 2013) [3, 4] are shown in Fig 1.
2011–2012
Overall HER2 positivity (IHC score 3+ or amplified by FISH) was 13.8% (211 of 1528 cases).
185 of 1528 cases (12%) were 3+ on IHC, 181 of 1528 cases (12%) were amplified by FISH.
Six of 1528 cases were equivocal on FISH (0.3%). The one case with IHC score 3+ was con-
sidered as HER2 positive. The other five cases underwent repeated IHC/FISH testing on the
core biopsy or on a different tumor block, and none of them became amplified or IHC positive.
Data are shown in Table 1.
2013–2014
Overall HER2 positivity (IHC score 3+ or amplified by FISH) was 15.8% (98 of 617 cases were
either 3+ on IHC or amplified by FISH. 79 of 617 cases (13%) were 3+ on IHC, 96 of 617 cases
(15.5%) were amplified by FISH.
Fig 1. Diagrammatic representation of HER2 positivity rate in percentage in the periods of 2011–2012 (two years) and fromOctober 2013 to
October 2014 (12 months).
doi:10.1371/journal.pone.0140652.g001
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Equivocal cases by FISH were seen in 25 of 617 cases (4.1%). 22 of 25 equivocal cases (88%)
were either scores 1+ or 2+ on IHC. In 13 equivocal cases, there was a repeated IHC/FISH test-
ing: 2 of 13 cases (15%) became amplified by FISH, 1 of 13 cases (7.5%) was 3+ on IHC. The
other 10 cases remained negative or equivocal by FISH and score 1+ or score 2+ by IHC. Alto-
gether 3 of 13 (23%) equivocal cases on FISH and IHC became HER2 positive after re-testing.
Time to re-testing and to definitive diagnosis on HER2 status required up to 5 weeks (either
time to surgical specimen or to repeated assays on the preoperative core biopsies).
Data are shown in Table 2.
Discussion
In our study we could demonstrate, that overall HER2 positivity rate in breast cancer increased
in 2% after implementing the modified ASCO/CAP guidelines in 2013 on HER2 testing. Our
data show, that this increase is mainly due to newly defined cut-offs on FISH positivity,
whereas score 3+ on immunohistochemistry did not essentially influence the increase in HER2
positivity rate. Additionally, a relative high percentage of equivocal cases (up to 4%) were
observed by using these guidelines. This new phenomenon in our diagnostic HER2 testing,
being virtually absent prior to these guidelines, resulted in a considerable delay in the definitive
pathology report on HER2 status due to re-testing.
There is only limited data on long-term impact of the modified ASCO/CAP Guidelines in
the literature, as time passed since the official implementation of these guidelines encompasses
around one and half years first [8–13]. Nevertheless, the limited available studies consequently
report on the increase of HER2 positive breast cancer cases raining from to 1.4% to 7.3%using
the 2013 ASCO/CAP guidelines [8–11, 14]. Our data of 2% increase on overall HER2 positivity
corresponds to these early observations. The new guidelines offer a more wide definition on
score 2+ on immunohistochemistry, which consequently may result in more equivocal cases
on IHC as was reported recently [8, 10, 12]. The recommendation of the current guidelines
involve reflex testing of IHC score 2+ cases [4]. As reported by Sapino et al recently on a large
cohort of IHC score 2+ cases (n = 957), the percentage of amplified cases on ISH (in situ hybri-
disation) varies from 15–29.5%, even though the use of alternative polymerase chain reaction
Table 1. Concordance of test results in routine diagnostic HER2 assays in breast cancer. Immunohistochemistry (IHC) and FISH in 2011 and 2012.
IHC score 0 IHC score 1+ IHC score 2+ IHC score 3+
FISH ampliﬁed 3 (<1%) 3 (<0.5%) 20 (5%) 155 (84%)
FISH non-ampliﬁed 361 (>99%) 567 (>99%) 384 (94%) 29 (15.5%)
FISH equivocal - 1 (<0.5%) 4 (<1%) 1 (0.5%)
FISH monosomy - - - -
N = 1528 364 (100%) 571 (100%) 408 (100%) 185 (100%)
doi:10.1371/journal.pone.0140652.t001
Table 2. Concordance of test results in routine diagnostic HER2 assays in breast cancer. Immunohistochemistry (IHC) and FISH between Oct 2013
and Oct 2014
IHC score 0 IHC score 1+ IHC score 2+ IHC score 3+
FISH ampliﬁed - 4 (1.5%) 15 (8.5%) 77 (97.4%)
FISH non-ampliﬁed 112 (98.5%) 237 (95%) 145 (83%) 1 (1.3%)
FISH equivocal 2 (2%) 7 (3%) 15 (8.5%) 1 (1.3%)
FISH monosomy - 1 (0.5%) - -
N = 617 114 (100%) 249 (100%) 175 (100%) 79 (100%)
doi:10.1371/journal.pone.0140652.t002
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based technics as MLPA, the percentage of amplified IHC score 2+ cases did not exceed 25%
[12]. In our experience of the last 12 months, there was no significant increase of IHC score 2
+ cases (1.6% more using the 2013 guidelines), but a slight increase in score 3+ on IHC (by 1%
compared to the previous years) occurred in our experience.
Consequently to increased IHC score 2+ cases, the need for reflex testing with ISH technol-
ogy is also arising, resulting in higher workload in ISH, which reportedly can be up to doubling
the number of ISH assays when comparing numbers from using the previous guidelines in
some recent works [10, 15]. In our experience, the increase of FISH assays were mainly due to
equivocal cases on ISH, as the majority of these cases were IHC score 1+ or 2+, consisting
around 5% of the cohort. Following the recommendation of the current guidelines, equivocal
cases on IHC and FISH need to undergo further testing either on a further tumor block or on
the same sample if no further blocks are available [4]. Our cohort, we reached in 23% of the ini-
tially equivocal cases, either an amplified status in FISH or IHC score 3+. Our data on re-test-
ing and positivity rate correspond to spare available literature data on re-testing data on IHC
and/or ISH equivocal cases [9, 12].
The question of reproducibility of modified scoring criteria was addressed by Bianchi et al
in a recent multicentre study [16]. Based on these data, there was a false negative rate of 24.6%
between the participating institutions using the updated guidelines, mainly due to the interpre-
tation issues, pointing out to the need of participation in internal and external quality assur-
ance programs [16].
Although the updated guidelines address issue on analytical validity and clinical utility,
there is also a recommendation on re-testing in cases with histopathological discrepancies as
downgrading in histological grade on excision specimens [4, 17–19]. The question of how justi-
fied this recommendation is in the view of relative low incidence of HER2 heterogeneity and of
the available resources of the given pathology institutions have been addressed recently by
Rakha et al [18, 20]. Furthermore, the change in definition of IHC score 2+ subsets being
scored as IHC score 1+ using the previous guidelines, raises further concern as efficacy and
availabilities within the routine diagnostic service [18]. In our experience, equivocal cases on
IHC and /or FISH, undergoing re-testing, resulted in a few weeks delay until a definitive diag-
nosis on HER2 status became possible. As also pointed out by the ASCO/CAP panel recently,
guidelines need revision if further evidence based data will be available after the implementa-
tion of these recommendations [20].
Conclusions
In conclusion it can be stated, that implementing the modified ASCO/CAP Guidelines from
2013 resulted in an increase of 2% in overall HER2 positivity rate in comparison to overall pos-
itivity rate by applying the previous ASCO/CAP guidelines. The high rate of equivocal cases
(4.1%) did not considerably contribute to the increase in overall HER2 positivity, but resulted
in delay of the definitive diagnosis on HER2 status. Further data and experiences from diagnos-
tic HER2 services are needed to be collected and prospectively analysed so that adjustments in
the guidelines can be met based on evidence and experience.
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